All Stories

  1. Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory Diseases

    Article • Clinical Pharmacokinetics, August 2026, Springer Science + Business Media

    Erwin Dreesen

  2. Precision Dosing of Vancomycin: A Systematic Review of Population Pharmacokinetics Models and Comparative Evaluation of Software Tools

    Article • Clinical Pharmacokinetics, May 2026, Springer Science + Business Media

    Erwin Dreesen

  3. Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn’s Disease

    Article • Clinical Pharmacokinetics, April 2026, Springer Science + Business Media

    Erwin Dreesen

  4. Response to Shen et al

    Article • The American Journal of Gastroenterology, April 2026, Wolters Kluwer Health

    Erwin Dreesen

  5. Systematic review and scoring‐based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children

    Article • British Journal of Clinical Pharmacology, March 2026, Wiley

    Professor karel allegaert , Erwin Dreesen

  6. High Doses of Antidepressants and Long-term Treatment of Obsessive-compulsive Disorder: Another Barrier to Accessing Deep Brain Stimulation?

    Article • ALPHA PSYCHIATRY, October 2025, IMR Press

    Erwin Dreesen

  7. A fluconazole population pharmacokinetics study to improve target attainment in critically ill patients

    Article • Infection, October 2025, Springer Science + Business Media

    Erwin Dreesen

  8. Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s Disease

    Article • Clinical Gastroenterology and Hepatology, September 2025, Elsevier

    Erwin Dreesen

  9. Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics study

    Article • Journal of Crohn s and Colitis, August 2025, Oxford University Press (OUP)

    Erwin Dreesen

  10. The Gravity of a Unique Subcutaneous Anti-IL23 Induction Regimen

    Article • Gastroenterology, August 2025, Elsevier

    Erwin Dreesen

  11. Response to Dai et al.

    Article • The American Journal of Gastroenterology, July 2025, Wolters Kluwer Health

    Erwin Dreesen

  12. Population pharmacokinetics of edoxaban in geriatric patients with atrial fibrillation

    Article • Journal of Thrombosis and Haemostasis, July 2025, Elsevier

    Erwin Dreesen

  13. A Multiple Imputation Workflow for Handling Missing Covariate Data in Pharmacometrics Modeling

    Article • CPT Pharmacometrics & Systems Pharmacology, May 2025, Wiley

    Erwin Dreesen

  14. A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases

    Article • The American Journal of Gastroenterology, April 2025, Wolters Kluwer Health

    Erwin Dreesen

  15. Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease

    Article • Pharmaceutics, February 2025, MDPI AG

    Erwin Dreesen

  16. Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis

    Article • The Lancet Gastroenterology & Hepatology, January 2025, Elsevier

    Erwin Dreesen

  17. Model-informed precision dosing in inflammatory bowel diseases

    Article • Trends in Pharmacological Sciences, January 2025, Elsevier

    Erwin Dreesen

  18. Tracking the journey: Gastrointestinal transit and intraluminal pH dynamics in aging populations using wireless motility capsule

    Article • International Journal of Pharmaceutics, January 2025, Elsevier

    Erwin Dreesen, Associate Prof Christophe Matthys

  19. Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis

    Article • Infection, December 2024, Springer Science + Business Media

    Erwin Dreesen

  20. Dose Optimization of Amikacin in the Emergency Department: A Population Pharmacokinetics Simulation Study

    Article • Therapeutic Drug Monitoring, December 2024, Wolters Kluwer Health

    Erwin Dreesen

  21. Model-informed precision dosing: State of the art and future perspectives

    Article • Advanced Drug Delivery Reviews, December 2024, Elsevier

    Erwin Dreesen

  22. Human serum albumin: prediction model and reference values for preterm and term neonates

    Article • Pediatric Research, October 2024, Springer Science + Business Media

    Professor karel allegaert , Erwin Dreesen

  23. Correction: Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools

    Article • Clinical Pharmacokinetics, October 2024, Springer Science + Business Media

    Erwin Dreesen

  24. Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools

    Article • Clinical Pharmacokinetics, September 2024, Springer Science + Business Media

    Erwin Dreesen

  25. Decreased Kidney Function Explains Higher Vancomycin Exposure in Older Adults

    Article • Drugs & Aging, August 2024, Springer Science + Business Media

    Erwin Dreesen

  26. Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study

    Article • JEADV Clinical Practice, July 2024, Wiley

    Erwin Dreesen

  27. The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism

    Article • Cellular Oncology, June 2024, Springer Science + Business Media

    Erwin Dreesen

  28. Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study

    Article • Journal of Antimicrobial Chemotherapy, June 2024, Oxford University Press (OUP)

    Erwin Dreesen

  29. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease

    Article • Clinics and Research in Hepatology and Gastroenterology, June 2024, Elsevier

    Erwin Dreesen

  30. Exposure–response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis

    Article • Journal of the European Academy of Dermatology and Venereology, May 2024, Wiley

    Erwin Dreesen

  31. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

    Article • Therapeutic Drug Monitoring, April 2024, Wolters Kluwer Health

    Erwin Dreesen

  32. The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism

    Article • April 2024, Research Square

    Erwin Dreesen

  33. Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole

    Article • Clinical Pharmacokinetics, March 2024, Springer Science + Business Media

    Erwin Dreesen

  34. Do we perceive sensations inside and outside of our body differently? Perceptual, emotional, and behavioral differences between visceral and somatic sensation, discomfort, and pain

    Article • Neurogastroenterology & Motility, March 2024, Wiley

    Erwin Dreesen

  35. Agreement Between a Colorimetric Assay and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Quantifying Paracetamol Plasma Concentrations

    Article • The AAPS Journal, February 2024, Springer Science + Business Media

    Professor karel allegaert , Erwin Dreesen

  36. Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe

    Article • Basic & Clinical Pharmacology & Toxicology, January 2024, Wiley

    Erwin Dreesen

  37. Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease

    Article • Journal of Pediatric Gastroenterology and Nutrition, December 2023, Wiley

    Erwin Dreesen

  38. Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study

    Article • Clinical Gastroenterology and Hepatology, November 2023, Elsevier

    Erwin Dreesen

  39. TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde‐Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology

    Article • Clinical Pharmacology & Therapeutics, September 2023, Wiley

    Erwin Dreesen

  40. Therapeutic Drug Monitoring 2.0: Time to Assemble the Puzzle

    Article • Inflammatory Bowel Diseases, August 2023, Oxford University Press (OUP)

    Erwin Dreesen

  41. Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates

    Article • Pharmaceutics, June 2023, MDPI AG

    Erwin Dreesen

  42. Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review

    Article • Antibiotics, June 2023, MDPI AG

    Erwin Dreesen

  43. A personalised taper-to-target strategy with adalimumab in Crohn's disease

    Article • The Lancet Gastroenterology & Hepatology, April 2023, Elsevier

    Erwin Dreesen

  44. Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review

    Article • Clinical Pharmacokinetics, March 2023, Springer Science + Business Media

    Erwin Dreesen

  45. A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases

    Article • Journal of Crohn s and Colitis, January 2023, Oxford University Press (OUP)

    Erwin Dreesen

  46. Erratum to: Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies

    Article • Journal of Crohn s and Colitis, November 2022, Oxford University Press (OUP)

    Erwin Dreesen

  47. Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study

    Article • Medical Mycology, September 2022, Oxford University Press (OUP)

    Erwin Dreesen

  48. Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults

    Article • Pharmaceutics, July 2022, MDPI AG

    Professor karel allegaert , Erwin Dreesen

  49. Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia

    Article • Journal of Antimicrobial Chemotherapy, July 2022, Oxford University Press (OUP)

    Erwin Dreesen

  50. Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases

    Article • CPT Pharmacometrics & Systems Pharmacology, June 2022, Wiley

    Erwin Dreesen

  51. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders

    Article • Frontiers in Immunology, June 2022, Frontiers

    Erwin Dreesen

  52. Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice

    Article • Frontiers in Pharmacology, May 2022, Frontiers

    Erwin Dreesen

  53. Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA‐FLU study

    Article • Mycoses, April 2022, Wiley

    Erwin Dreesen

  54. Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis

    Article • Clinical and Experimental Dermatology, April 2022, Oxford University Press (OUP)

    Erwin Dreesen

  55. The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis

    Article • Intensive Care Medicine, March 2022, Springer Science + Business Media

    Erwin Dreesen

  56. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies

    Article • Journal of Crohn s and Colitis, January 2022, Oxford University Press (OUP)

    Erwin Dreesen

  57. Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia

    Article • International Journal of Antimicrobial Agents, January 2022, Elsevier

    Erwin Dreesen

  58. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function

    Article • Infection and Drug Resistance, January 2022, Taylor & Francis

    Erwin Dreesen

  59. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy

    Article • The Journal of Pediatrics, January 2022, Elsevier

    Erwin Dreesen

  60. Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases

    Article • Expert Review of Clinical Pharmacology, December 2021, Taylor & Francis

    Erwin Dreesen

  61. Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study

    Article • Inflammatory Bowel Diseases, November 2021, Oxford University Press (OUP)

    Erwin Dreesen

  62. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis

    Article • Pharmaceutics, October 2021, MDPI AG

    Erwin Dreesen

  63. Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes

    Article • Journal of Pharmacology and Experimental Therapeutics, October 2021, Elsevier

    Erwin Dreesen

  64. Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model

    Article • Pharmaceutics, September 2021, MDPI AG

    Tomaž Vovk, Erwin Dreesen

  65. Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates

    Article • Journal of Antimicrobial Chemotherapy, September 2021, Oxford University Press (OUP)

    Professor karel allegaert , Erwin Dreesen

  66. New Tools for Therapeutic Drug Monitoring: Making Big Things out of Small Pieces

    Article • Journal of Crohn s and Colitis, August 2021, Oxford University Press (OUP)

    Erwin Dreesen

  67. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication

    Article • Therapeutic Drug Monitoring, August 2021, Wolters Kluwer Health

    Professor karel allegaert , Erwin Dreesen

  68. Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis

    Article • European Journal of Drug Metabolism and Pharmacokinetics, July 2021, Springer Science + Business Media

    Erwin Dreesen

  69. Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease

    Article • British Journal of Clinical Pharmacology, July 2021, Wiley

    Erwin Dreesen

  70. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

    Article • Nature Communications, July 2021, Springer Science + Business Media

    Johan Neyts, Erwin Dreesen

  71. Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens”

    Article • EBioMedicine, July 2021, Elsevier

    Johan Neyts, Erwin Dreesen

  72. Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study

    Article • Inflammatory Bowel Diseases, June 2021, Oxford University Press (OUP)

    Erwin Dreesen

  73. Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis

    Article • Microorganisms, June 2021, MDPI AG

    Erwin Dreesen

  74. Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics

    Article • Mycoses, May 2021, Wiley

    Erwin Dreesen

  75. Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study

    Article • Antibiotics, May 2021, MDPI AG

    Erwin Dreesen

  76. P344 Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis

    Article • Journal of Crohn s and Colitis, May 2021, Oxford University Press (OUP)

    Erwin Dreesen

  77. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease

    Article • Clinical Gastroenterology and Hepatology, May 2021, Elsevier

    Erwin Dreesen

  78. P280 Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies

    Article • Journal of Crohn s and Colitis, May 2021, Oxford University Press (OUP)

    Erwin Dreesen

  79. P307 Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn’s disease

    Article • Journal of Crohn s and Colitis, May 2021, Oxford University Press (OUP)

    Erwin Dreesen

  80. P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases

    Article • Journal of Crohn s and Colitis, May 2021, Oxford University Press (OUP)

    Erwin Dreesen

  81. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

    Article • EBioMedicine, April 2021, Elsevier

    Johan Neyts, Erwin Dreesen

  82. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases

    Article • British Journal of Clinical Pharmacology, March 2021, Wiley

    Erwin Dreesen

  83. Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation

    Article • Journal of Antimicrobial Chemotherapy, January 2021, Oxford University Press (OUP)

    Erwin Dreesen

  84. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies

    Article • January 2021, Elsevier

    Erwin Dreesen

  85. Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues

    Article • Current Opinion in Pharmacology, December 2020, Elsevier

    Erwin Dreesen

  86. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

    Article • October 2020, Springer Science + Business Media

    Erwin Dreesen

  87. Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.

    Article • Frontiers in Pharmacology, June 2020, Frontiers

    Erwin Dreesen

  88. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease

    Article • British Journal of Clinical Pharmacology, June 2020, Wiley

    Erwin Dreesen

  89. Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?

    Article • Frontiers in Pharmacology, May 2020, Frontiers

    Erwin Dreesen

  90. Reply

    Article • Clinical Gastroenterology and Hepatology, March 2020, Elsevier

    Erwin Dreesen

  91. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease

    Article • Clinical Gastroenterology and Hepatology, March 2020, Elsevier

    Erwin Dreesen

  92. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission

    Article • Clinical Gastroenterology and Hepatology, February 2020, Elsevier

    Erwin Dreesen, Tomaž Vovk

  93. Reply

    Article • Clinical Gastroenterology and Hepatology, January 2020, Elsevier

    Erwin Dreesen

  94. Monocyte-Driven Atypical Cytokine Storm and Aberrant Neutrophil Activation as Key Mediators of COVID19 Disease Severity

    Article • SSRN Electronic Journal, January 2020, Elsevier

    Johan Neyts, Erwin Dreesen

  95. Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study

    Article • SSRN Electronic Journal, January 2020, Elsevier

    Johan Neyts, Erwin Dreesen

  96. How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?

    Article • Clinical Gastroenterology and Hepatology, October 2019, Elsevier

    Erwin Dreesen

  97. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients

    Article • Journal of Crohn s and Colitis, August 2019, Oxford University Press (OUP)

    Erwin Dreesen

  98. A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, August 2019, Oxford University Press (OUP)

    Erwin Dreesen

  99. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease

    Article • Journal of Pediatric Gastroenterology and Nutrition, June 2019, Wolters Kluwer Health

    Erwin Dreesen

  100. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

    Article • Therapeutic Drug Monitoring, June 2019, Wolters Kluwer Health

    Erwin Dreesen

  101. Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases

    Article • Therapeutic Drug Monitoring, April 2019, Wolters Kluwer Health

    Erwin Dreesen

  102. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study

    Article • Journal of Crohn s and Colitis, March 2019, Oxford University Press (OUP)

    Erwin Dreesen

  103. Optimising infliximab induction dosing for patients with ulcerative colitis

    Article • British Journal of Clinical Pharmacology, February 2019, Wiley

    Erwin Dreesen

  104. Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

    Article • Journal of Crohn s and Colitis, February 2019, Oxford University Press (OUP)

    Erwin Dreesen

  105. P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis

    Article • Journal of Crohn s and Colitis, January 2019, Oxford University Press (OUP)

    Erwin Dreesen

  106. P342 A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy

    Article • Journal of Crohn s and Colitis, January 2019, Oxford University Press (OUP)

    Erwin Dreesen

  107. P265 Pharmacokinetic and pharmacodynamic evaluation of radiological healing in Crohn’s disease patients treated with Infliximab: a TAILORIX MRE substudy

    Article • Journal of Crohn s and Colitis, January 2019, Oxford University Press (OUP)

    Erwin Dreesen

  108. P408 Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease

    Article • Journal of Crohn s and Colitis, January 2019, Oxford University Press (OUP)

    Erwin Dreesen

  109. OP25 Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease

    Article • Journal of Crohn s and Colitis, January 2019, Oxford University Press (OUP)

    Erwin Dreesen

  110. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

    Article • Clinical Gastroenterology and Hepatology, December 2018, Elsevier

    Erwin Dreesen

  111. Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, October 2018, Wiley

    Erwin Dreesen

  112. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

    Article • Journal of Crohn s and Colitis, September 2018, Oxford University Press (OUP)

    Erwin Dreesen

  113. Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

    Article • Cochrane Database of Systematic Reviews, July 2018, Wiley

    Erwin Dreesen

  114. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment

    Article • Current Drug Targets, April 2018, Bentham Science Publishers

    Erwin Dreesen

  115. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

    Article • Alimentary Pharmacology & Therapeutics, December 2017, Wiley

    Erwin Dreesen

  116. Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time

    Article • Inflammatory Bowel Diseases, December 2017, Oxford University Press (OUP)

    Erwin Dreesen

  117. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

    Article • Clinical Pharmacology Advances and Applications, October 2017, Dove Medical Press

    Erwin Dreesen, Denis Mulleman

  118. Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics

    Article • Therapeutic Drug Monitoring, August 2017, Wolters Kluwer Health

    Erwin Dreesen

  119. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic–Pharmacodynamic Modeling

    Article • Therapeutic Drug Monitoring, August 2017, Wolters Kluwer Health

    Erwin Dreesen

  120. Anti-Infliximab Antibody Concentrations Guide Therapeutic Decision-Making in Patients with Crohn's Disease Losing Clinical Response

    Article • Gastroenterology, April 2017, Elsevier

    Erwin Dreesen

  121. Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment

    Article • Gastroenterology, April 2017, Elsevier

    Erwin Dreesen

  122. Recent Anti-TNF Exposure Predicts Lower Vedolizumab Trough Concentrations in Patients with Crohn Disease

    Article • Gastroenterology, April 2017, Elsevier

    Erwin Dreesen

  123. Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?

    Article • Journal of Crohn s and Colitis, March 2017, Oxford University Press (OUP)

    Erwin Dreesen

  124. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease

    Article • The American Journal of Gastroenterology, October 2016, Wolters Kluwer Health

    Erwin Dreesen

  125. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

    Article • Inflammatory Bowel Diseases, April 2016, Oxford University Press (OUP)

    Erwin Dreesen

  126. Sa1943 Variability in Vedolizumab Exposure Between Patients With Inflammatory Bowel Disease

    Article • Gastroenterology, April 2016, Elsevier

    Erwin Dreesen

  127. Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

    Article • Journal of Crohn s and Colitis, January 2016, Oxford University Press (OUP)

    Erwin Dreesen

  128. Neutralisation of Soluble Tumor Necrosis Factor

    Article • Karger Publishers

    Erwin Dreesen